Janux Therapeutics, Inc. (JANX)

Market Cap	1.54B
Revenue (ttm)	9.34M
Net Income (ttm)	-77.74M
Shares Out	59.18M
EPS (ttm)	-1.37
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,451,784
Open	26.51
Previous Close	25.56
Day's Range	25.36 - 27.17
52-Week Range	22.52 - 71.71
Beta	3.24
Analysts	Strong Buy
Price Target	94.29 (+261.82%)
Earnings Date	May 8, 2025

About JANX

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients with cancer. Its clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phas...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 11, 2021
• Employees: 81
• Stock Exchange: NASDAQ
• Ticker Symbol: JANX
• Website: https://www.januxrx.com

Financial Performance

In 2024, Janux Therapeutics's revenue was $10.59 million, an increase of 30.99% compared to the previous year's $8.08 million. Losses were -$68.99 million, 18.4% more than in 2023.

Analyst Forecast

According to 7 analysts, the average rating for JANX stock is "Strong Buy." The 12-month stock price forecast is $94.29, which is an increase of 261.82% from the latest price.

Price Target

$94.29

(261.82% upside)

Analyst Consensus: Strong Buy